SI2626350T1 - Spojina ciklopropana - Google Patents

Spojina ciklopropana

Info

Publication number
SI2626350T1
SI2626350T1 SI201130507T SI201130507T SI2626350T1 SI 2626350 T1 SI2626350 T1 SI 2626350T1 SI 201130507 T SI201130507 T SI 201130507T SI 201130507 T SI201130507 T SI 201130507T SI 2626350 T1 SI2626350 T1 SI 2626350T1
Authority
SI
Slovenia
Prior art keywords
cyclopropane compound
cyclopropane
compound
Prior art date
Application number
SI201130507T
Other languages
English (en)
Inventor
Taro Terauchi
Ayumi Takemura
Takashi Doko
Yu Yoshida
Toshiaki Tanaka
Keiichi Sorimachi
Yoshimitsu Naoe
Carsten Beuckmann
Yuji Kazuta
Original Assignee
Eisai R&D Management Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co., Ltd. filed Critical Eisai R&D Management Co., Ltd.
Publication of SI2626350T1 publication Critical patent/SI2626350T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/34One oxygen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI201130507T 2010-09-22 2011-09-20 Spojina ciklopropana SI2626350T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38534210P 2010-09-22 2010-09-22
JP2010211629 2010-09-22
PCT/JP2011/071325 WO2012039371A1 (ja) 2010-09-22 2011-09-20 シクロプロパン化合物
EP11826816.8A EP2626350B1 (en) 2010-09-22 2011-09-20 Cyclopropane compound

Publications (1)

Publication Number Publication Date
SI2626350T1 true SI2626350T1 (sl) 2015-09-30

Family

ID=45873858

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201130507T SI2626350T1 (sl) 2010-09-22 2011-09-20 Spojina ciklopropana

Country Status (28)

Country Link
US (1) US8268848B2 (sl)
EP (1) EP2626350B1 (sl)
JP (1) JP4944286B1 (sl)
KR (1) KR101458007B1 (sl)
CN (1) CN103153963B (sl)
AR (1) AR083060A1 (sl)
AU (1) AU2011304285B2 (sl)
BR (1) BR112013006594B1 (sl)
CA (1) CA2811895C (sl)
CL (1) CL2013000784A1 (sl)
DK (1) DK2626350T3 (sl)
ES (1) ES2540851T3 (sl)
IL (1) IL225437A (sl)
JO (1) JO2990B1 (sl)
MA (1) MA34609B1 (sl)
MX (1) MX2013003218A (sl)
MY (1) MY160969A (sl)
NZ (1) NZ609313A (sl)
PE (1) PE20131162A1 (sl)
PL (1) PL2626350T3 (sl)
PT (1) PT2626350E (sl)
RS (1) RS54101B1 (sl)
RU (1) RU2571414C2 (sl)
SG (1) SG188585A1 (sl)
SI (1) SI2626350T1 (sl)
TW (1) TWI516484B (sl)
UA (1) UA108510C2 (sl)
WO (1) WO2012039371A1 (sl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2814798B1 (en) 2012-02-17 2019-04-03 Eisai R&D Management Co., Ltd. Methods and compounds useful in the synthesis of orexin-2 receptor antagonists
WO2014081619A1 (en) * 2012-11-20 2014-05-30 Merck Sharp & Dohme Corp. Pyrimidine pde10 inhibitors
RU2681937C2 (ru) * 2014-08-06 2019-03-14 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ получения пиримидин-1-олового соединения и его промежуточного соединения
SG10202007759RA (en) * 2014-10-23 2020-09-29 Eisai R&D Man Co Ltd Compositions and methods for treating insomnia
BR112018008294A2 (pt) 2015-10-29 2018-10-30 Univ Tsukuba derivado de morfinan, fármaco farmacêutico, composição farmacêutica, antagonista do receptor de orexina, e, agente terapêutico ou profilático e método terapêutico ou profilático.
AU2017264871B2 (en) 2016-05-12 2023-03-16 Eisai R&D Management Co., Ltd. Methods of treating circadian rhythm sleep disorders
JP7179049B2 (ja) 2017-08-01 2022-11-28 ベルゲン ファーマシューティカル、 エルエルシー オレキシン受容体拮抗薬の結晶形及びその製造方法並びに用途
US20220194925A1 (en) * 2019-05-15 2022-06-23 Eisai R&D Management Co., Ltd. Method and compound useful in preparation of orexin-2 receptor antagonist, and lemborexant having few impurities
CA3144067A1 (en) * 2019-06-26 2020-12-30 Eisai R&D Management Co., Ltd. Lemborexant for treating sleep issues
JP2023506025A (ja) 2019-12-11 2023-02-14 テバ チェコ インダストリーズ エス.アール.オー. レンボレキサントの固体形態
CN115003305A (zh) 2019-12-20 2022-09-02 卫材R&D管理有限公司 使用莱博雷生治疗失眠
KR20220129538A (ko) 2020-01-16 2022-09-23 에자이 알앤드디 매니지먼트 가부시키가이샤 렘보렉산트의 약물 물질 및 이를 포함하는 의약 조성물
WO2021205648A1 (ja) * 2020-04-10 2021-10-14 国立大学法人東海国立大学機構 精神障害患者の客観的睡眠評価方法
WO2023007320A1 (en) 2021-07-26 2023-02-02 Eisai R&D Mangement Co., Ltd. Lemborexant for use in methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases
WO2023178693A1 (zh) * 2022-03-25 2023-09-28 浙江华海药业股份有限公司 一种莱博雷生及其中间体的制备方法
WO2023178702A1 (zh) * 2022-03-25 2023-09-28 浙江华海药业股份有限公司 莱博雷生及其中间体化合物的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06328057A (ja) 1993-05-26 1994-11-29 Sanyo Electric Co Ltd 厨芥処理装置
CA2220036A1 (en) 1995-05-05 1996-11-07 Human Genome Sciences, Inc. Human neuropeptide receptor
BR9713690B1 (pt) * 1996-12-10 2009-08-11 agentes melatoninérgicos benzodioxola, benzofurano, diidrobenzofurano e benzodioxano.
US6309854B1 (en) 1996-12-17 2001-10-30 Smithkline Beecham Corporation Polynucleotides encoding ligands of the neuropeptide receptor HFGAN72
US6001963A (en) 1996-12-17 1999-12-14 Smithkline Beecham Corporation Ligands of the neuropeptide receptor HFGAN72
US6020157A (en) 1997-04-30 2000-02-01 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72X receptor
US5935814A (en) 1997-04-30 1999-08-10 Smithkline Beecham Corporation Polynucleotides encoding HFGAN72Y receptor
US6166193A (en) 1997-07-25 2000-12-26 Board Of Regents, University Of Texas System Polynucleotides encoding MY1 receptor
CN1926109B (zh) 2004-03-01 2011-04-13 埃科特莱茵药品有限公司 经取代的1,2,3,4-四氢异喹啉衍生物
WO2006033005A2 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Thrombopoietin receptor agonists
CN101155792A (zh) * 2005-04-12 2008-04-02 默克公司 氨基丙氧基苯基增食欲素受体拮抗剂
AU2006235302A1 (en) * 2005-04-12 2006-10-19 Merck & Co., Inc. Amidopropoxyphenyl orexin receptor antagonists
JP2006328057A (ja) * 2005-04-25 2006-12-07 Eisai R & D Management Co Ltd 抗不安薬及びそのスクリーニング方法
US20090082394A1 (en) 2006-03-15 2009-03-26 Actelion Pharmaceuticals, Ltd. Tetrahydroisoquinoline Derivatives to Enhance Memory Function
WO2007129188A1 (en) 2006-05-10 2007-11-15 Pfizer Japan Inc. Cyclopropanecarboxamide compound
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
CA2662538A1 (en) 2006-09-11 2008-03-20 Glaxo Group Limited Azabicyclic compounds as inhibitors of monoamines reuptake
JP2010504957A (ja) * 2006-09-29 2010-02-18 アクテリオン ファーマシューティカルズ リミテッド 3−アザ−ビシクロ[3.1.0]ヘキサン誘導体
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CL2007003827A1 (es) * 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
KR20100075444A (ko) 2007-09-21 2010-07-02 사노피-아벤티스 (사이클로프로필-페닐)-페닐-옥살아미드, 이의 제조 방법 및 의약으로서의 이의 용도
PE20091010A1 (es) 2007-10-10 2009-08-08 Actelion Pharmaceuticals Ltd Derivados de tetrahidroquinolina
AU2009324239A1 (en) * 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(IR,4S,6R-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0]hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
US20120165339A1 (en) * 2010-12-22 2012-06-28 Eisai R&D Management Co., Ltd. Cyclopropane derivatives

Also Published As

Publication number Publication date
US20120095031A1 (en) 2012-04-19
KR20130097776A (ko) 2013-09-03
AU2011304285B2 (en) 2015-01-29
JPWO2012039371A1 (ja) 2014-02-03
WO2012039371A1 (ja) 2012-03-29
CA2811895C (en) 2015-12-08
NZ609313A (en) 2014-05-30
TWI516484B (zh) 2016-01-11
JP4944286B1 (ja) 2012-05-30
RS54101B1 (en) 2015-10-30
MX2013003218A (es) 2013-06-28
AR083060A1 (es) 2013-01-30
RU2013117464A (ru) 2014-10-27
BR112013006594B1 (pt) 2021-08-17
TW201305129A (zh) 2013-02-01
DK2626350T3 (en) 2015-06-29
PL2626350T3 (pl) 2015-08-31
EP2626350A4 (en) 2014-02-12
KR101458007B1 (ko) 2014-11-04
CN103153963B (zh) 2014-12-24
PE20131162A1 (es) 2013-10-19
EP2626350B1 (en) 2015-04-15
ES2540851T3 (es) 2015-07-14
SG188585A1 (en) 2013-04-30
UA108510C2 (en) 2015-05-12
CA2811895A1 (en) 2012-03-29
MY160969A (en) 2017-03-31
MA34609B1 (fr) 2013-10-02
CN103153963A (zh) 2013-06-12
EP2626350A1 (en) 2013-08-14
JO2990B1 (ar) 2016-09-05
IL225437A (en) 2015-05-31
US8268848B2 (en) 2012-09-18
BR112013006594A2 (pt) 2016-06-21
CL2013000784A1 (es) 2013-07-05
RU2571414C2 (ru) 2015-12-20
PT2626350E (pt) 2015-08-03
IL225437A0 (en) 2013-06-27
AU2011304285A1 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
EP2590647A4 (en) PRO-NEUROGENIC COMPOUNDS
GB201015949D0 (en) Compounds
GB201008134D0 (en) Compounds
SI2626350T1 (sl) Spojina ciklopropana
EP2605658A4 (en) SPIROXAZOLIDINONVERBINDUNGEN
GB201007347D0 (en) Compounds
EP2649050A4 (en) LINKS
HK1188597A1 (en) Continuous arycyclic compound
GB201002563D0 (en) Compounds
GB201008209D0 (en) Compounds
GB201001688D0 (en) Compounds
GB201002911D0 (en) Compound
GB201017315D0 (en) Compound
GB201007789D0 (en) Novel Compound
GB201002216D0 (en) Compounds
GB201015537D0 (en) Compounds
GB201008210D0 (en) Compounds
GB201001796D0 (en) Compounds
GB201007209D0 (en) Compound
HK1184454A1 (en) Cyclopropane compound
GB201021228D0 (en) Compound
GB201015798D0 (en) Compound
GB201008820D0 (en) Compound
GB201005980D0 (en) Compound
GB201002810D0 (en) Novel compound